Real-world Data on Gi(l)Otrif Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 31 May 2017 Planned End Date changed from 1 Jun 2017 to 30 Sep 2017.
- 31 May 2017 Planned primary completion date changed from 1 Jun 2017 to 30 Sep 2017.
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.